Aclarion, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of Aclarion, Inc.'s 2024 Annual Meeting of Stockholders held on December 31, 2024. The report was filed on January 3, 2025. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Broomfield, Colorado.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder votes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
Seven proposals were submitted to a vote of security holders, and all were approved by the stockholders:
- Proposal 1: Election of seven directors (Jeffrey Thramann, Brent Ness, Stephen Deitsch, Scott Breidbart, David Neal, William Wesemann, and Amanda William). All nominees were elected.
- Proposal 2: Ratification of the appointment of Haynie & Company as the independent registered accounting firm.
- Proposal 3: Approval of the issuance of shares pursuant to the Company's equity line.
- Proposal 4: Approval of the issuance of shares pursuant to the Company's Series B convertible preferred stock.
- Proposal 5: Approval of the issuance of shares pursuant to the Company's Series C convertible preferred stock and related warrants.
- Proposal 6: Approval of a proposed reverse stock split.
- Proposal 7: Approval of an amendment to the 2022 equity incentive plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific discussion of risks and contingencies beyond the standard disclosure of the voting outcomes. The approval of the reverse stock split and various equity issuances indicates a strategic shift in capital structure, though specific terms are not detailed in this summary.
Key Facts for Investor Verification
- Verify the implementation timeline and ratio of the approved reverse stock split (Proposal 6).
- Confirm the specific terms and dilution impact of the approved equity line, Series B, and Series C convertible preferred stock issuances (Proposals 3, 4, and 5).
- Review the details of the amendment to the 2022 equity incentive plan (Proposal 7) to understand changes to employee compensation structures.
- Monitor the company's compliance with Nasdaq listing requirements following the reverse stock split.